Furthermore, tumor cells engineered to secrete soluble monomeric NKG2D ligands – which block but do not activate NKG2D – increase the responsiveness of tumor-infiltrating NK cells and enhance tumor rejection (Deng et al., 2015). The gene discussed is KLRK1; the disease is neoplasm.